✦ LIBER ✦

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

✍ Scribed by Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura, Akira Ono, Nozomu Machida, Kentaro Yamazaki, Junichiro Watanabe, Ana Ruiz-Garcia, Keiji Imai, Emiko Ohki, Nobuyuki Yamamoto

Book ID: 118299082
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 481 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-011-9789-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

53LBA A phase I/IIa study of icotinib hy

53LBA A phase I/IIa study of icotinib hydrochloride (BPI-2009H), an oral epidermal growth factor receptor tyrosine kinases inhibitor, in patients with advanced non-small-cell lung cancer and other solid tumors

✍ Q. Zhao; J. Zhou; J. Shentu; L. Wu; N. Xu; F. Tan; Y. Wang; D. Yang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I, pharmacokinetic (PK) and biolog

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Phase I–IIa study of BMS-690514, an EGFR

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

✍ Soria, Jean-Charles; Baselga, José; Hanna, Nasser; Laurie, Scott A.; Bahleda, Ra 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 343 KB